GlassScriptPhysician profile
Maureen L Aarons
NPI 1891789186
$2,795.35
in general payments reported to CMS, 2019-2025
26 companies · $225 in 2025
The $225 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,023 · 2020: $102 · 2021: $345 · 2022: $685 · 2023: $257 · 2024: $159 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $426 · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $426.28 |
| Education | $214.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $418.15 | 2019-2025 | |
| Amgen INC. | $255.80 | 2019-2024 | Otezla |
| Abbvie INC. | $254.78 | 2019-2025 | Rinvoq |
| Janssen Biotech, INC. | $212.41 | 2023-2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $197.64 | 2019-2024 | Cabtreo |
| Mayne Pharma Commercial LLC | $179.78 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $175.72 | 2019-2022 | |
| Galderma Laboratories, L.P. | $157.67 | 2019-2025 | Aklief, Nemluvio |
| Leo Pharma INC. | $141.63 | 2019-2022 | |
| Pfizer INC. | $121.57 | 2019-2023 | |
| Almirall LLC | $86.27 | 2019-2024 | Klisyri |
| Ucb, INC. | $79.89 | 2019-2024 | Bimzelx, Cimzia |
| Genzyme Corporation | $73.23 | 2019 | |
| Vyne Pharmaceuticals INC. | $63.91 | 2020-2021 | |
| Biofrontera INC. | $59.68 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $55.75 | 2019-2025 | Ebglyss |
| Celgene Corporation | $41.55 | 2019 | |
| Arcutis Biotherapeutics, INC. | $34.51 | 2024-2025 | Zoryve |
| Dusa Pharmaceuticals, INC. | $33.55 | 2019 | |
| Novartis Pharmaceuticals Corporation | $31.65 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $28.39 | 2023 | Sotyktu |
| Incyte Corporation | $23.14 | 2021 | |
| Dermira, INC. | $23.01 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $18.29 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $15.30 | 2019 | |
| Mission Pharmacal Company | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Aarons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.